At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 116 enrolled
Drug / intervention
Pamiparib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
In Brief
A Phase 2 clinical trial evaluating Pamiparib, TMZ, and 1 other intervention for Brain and Central Nervous System Tumors. Completed, enrolled 116 participants across 22 sites in 5 countries.
Detailed Summary
The primary objective of this study is to evaluate the safety, efficacy and clinical activity of Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in participants with newly diagnosed or recurrent/refractory glioblastoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain and Central Nervous System Tumors
CountriesAustralia, France, Netherlands, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJul 2017
Primary CompletionMar 2021
TodayJul 2026
First PostedMay 12, 2017
Enrollment StartJul 24, 2017
Primary CompletionMar 17, 2021
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.1 years ago
Interventions
Pamiparibdrug
Administered as specified in the treatment arm
TMZdrug
Administered as specified in the treatment arm
Radiationradiation
Up to 60 Gy (total) over 6 - 7 weeks